mardi 12 novembre 2019

Onco Actu du 12 novembre 2019


2.6 ETIOLOGIE - ENVIRONNEMENT



5 Myths about Radon and Lung Cancer [Memorial Sloan Kettering Cancer Center]











3. PRÉVENTION



Shifting the Focus of Breast Cancer to Prevention [NY Times]











3.1 PRÉVENTION - TABAC



Top Trump official suggests tobacco regulation distracts from FDA mission [STAT]











3.1.1 PRÉVENTION - TABAC - E-CIGS



UK teen almost died from severe lung failure linked to vaping [New Scientist]











Vaping Illnesses Are Linked to Vitamin E Acetate, C.D.C. Says [NY Times]










U.S. CDC reports 'breakthrough' in vaping lung injury probe as cases top 2,000 [Reuters]











Trump to meet with vaping industry as he mulls tighter regulation [Reuters]











US officials identify ‘strong culprit’ in vaping illnesses [AP]











4.12 BIOPSIES LIQUIDES



Illumina Unveils Liquid Biopsy Version of TSO 500 Panel, Highlights Early User Validations [Genome Web]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Glutamine-Blocking Drug Slows Tumor Growth And Strengthens Anti-Tumor Response [Johns Hopkins]











5.10 TRAITEMENTS - ESSAIS



Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer [ESMO]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Cancer patient is first in Wales to get gene treatment [BBC News]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma [BMS]











Following a win for Bavencio, Pfizer and Merck KGaA continue PD-L1 losing streak [EndPoints]











Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer [EndPoints]











5.12.9 IMMUNOTHÉRAPIES - SITC



Bolt Bio preps clinical trials of immune-stimulating cancer drug in stubborn solid tumors [Fierce Biotech]











Nektar shows durability of Opdivo combo in 18-month update [Fierce Biotech]











NanoString Highlights the Results of Research Presented at the 2019 Annual Meeting of the Society of Immunotherapy for Cancer (SITC) [NanoString]











Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting [Nektar]











SITC – the morning after the night before [Vantage]










The latest Cinderella story in oncology ends with a sudden rout as updated data display spooks investors [EndPoints]











5.2 PHARMA



AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia [AbbVie]











5.2.6 PHARMA - BIOTECH



ASLAN Pharmaceuticals announces topline results from TreeTopp global pivotal study of varlitinib in biliary tract cancer [Aslan]











Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



France to Maintain Fast Track Schemes for Clinical Trials [RAPS]











6. LUTTE CONTRE LES CANCERS



Why NIH is beefing up its data sharing rules after 16 years [Science]










6.11 PATIENTS



I Thought Being a Health Care Reporter Would Make Cancer Easier. I Was Wrong. [Politico]










6.7 DMP, BIG DATA & APPLIS



Google Is Slurping Up Health Data—and It Looks Totally Legal [Wired]











Google signs healthcare data and cloud computing deal with Ascension [Reuters]











Google partners with major U.S. health system, gaining access to vast patient data in the process [STAT]